[
  {
    "ts": null,
    "headline": "Zimmer Biomet Holdings Inc. stock rises Friday, still underperforms market",
    "summary": "Zimmer Biomet Holdings Inc. stock rises Friday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=573de9e5cded14c9fdcee0284be55c0cf868c0532e5a4e7f0d549d5313b1a995",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735924320,
      "headline": "Zimmer Biomet Holdings Inc. stock rises Friday, still underperforms market",
      "id": 132338281,
      "image": "",
      "related": "ZBH",
      "source": "MarketWatch",
      "summary": "Zimmer Biomet Holdings Inc. stock rises Friday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=573de9e5cded14c9fdcee0284be55c0cf868c0532e5a4e7f0d549d5313b1a995"
    }
  },
  {
    "ts": null,
    "headline": "Zimmer Biomet price target raised to $113 from $110 at Evercore ISI",
    "summary": "Evercore ISI raised the firm’s price target on Zimmer Biomet (ZBH) to $113 from $110 and keeps an In Line rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – the ultimate source for",
    "url": "https://finnhub.io/api/news?id=6aa149e9eaa76481fd367be099dc5694b4a6a070f0dbeb4e3f34eb2fe2ec5760",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735905025,
      "headline": "Zimmer Biomet price target raised to $113 from $110 at Evercore ISI",
      "id": 132260242,
      "image": "https://media.zenfs.com/en/tipranks_452/100c3fef7d854fea083938dbb81d9e1c",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Evercore ISI raised the firm’s price target on Zimmer Biomet (ZBH) to $113 from $110 and keeps an In Line rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – the ultimate source for",
      "url": "https://finnhub.io/api/news?id=6aa149e9eaa76481fd367be099dc5694b4a6a070f0dbeb4e3f34eb2fe2ec5760"
    }
  }
]